Shares of Eli Lilly and Company rose to $728.45 during today's afternoon trading session. Despite the 3.3% change, the large-cap Pharmaceutical company still trades 23.57% above its average analyst target price of $589.49. So there may be further downside for the Pharmaceutical stock. Eli Lilly and Company has target prices ranging from $374.4 to $753.16 per share, and its average rating is buy.
Eli Lilly and Company's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.6%. The stock's short ratio is 1.63. The company's insiders own 0.16% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 84.2%. In conclusion, we believe there is mixed market sentiment regarding Eli Lilly and Company.
Institutions Invested in Eli Lilly and Company
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-12-31 | Lilly Endowment, Inc | 11% | 99,768,810 | $72,676,590,862 |
| 2023-09-30 | Vanguard Group Inc | 7% | 70,575,602 | $51,410,798,138 |
| 2023-09-30 | Blackrock Inc. | 7% | 65,673,934 | $47,840,178,023 |
| 2023-09-30 | PNC Financial Services Group, Inc. | 5% | 51,789,291 | $37,725,909,661 |
| 2023-09-30 | State Street Corporation | 4% | 33,406,858 | $24,335,226,117 |
| 2023-09-30 | FMR, LLC | 3% | 32,187,472 | $23,446,964,371 |
| 2023-09-30 | Capital World Investors | 3% | 26,860,053 | $19,566,205,935 |
| 2023-09-30 | Primecap Management Company | 2% | 23,063,536 | $16,800,633,080 |
| 2023-09-30 | Price (T.Rowe) Associates Inc | 2% | 22,235,992 | $16,197,808,643 |
| 2023-09-30 | State Farm Mutual Automobile Insurance Co | 2% | 17,157,660 | $12,498,497,636 |
